Navigation Links
Pharmalink AB Closes Deal With Grifols SA for the Acquisition of the Xepol(R) Programme for the Treatment of Post-Polio Syndrome
Date:6/30/2010

STOCKHOLM, June 30, 2010 /PRNewswire/ --

- Agreement Marks Milestone in Pharmalink's Corporate Development

Pharmalink AB, today announced that it has closed its agreement with Grifols SA for the acquisition of Pharmalink's Xepol(R) programme for the treatment of post-polio syndrome (PPS). The parties had previously announced reaching an agreement whereby Grifols would acquire all know-how and global intellectual property rights related to the use of human immunoglobulin for the treatment of (PPS) - the concept at the heart of the Xepol programme.

The agreement covers acquisition of one of Pharmalink's wholly owned subsidiaries and includes inter alia US, EU and Japan patents for the treatment of PPS with immunoglobulins, a US Orphan Drug Designation (ODD) for the use of immunoglobulin for the treatment of PPS and documentation of a number of clinical studies carried out in the recent years.

Johan Haggblad, Managing director of Pharmalink AB said: "This agreement marks a significant milestone in Pharmalink's corporate development. In developing a concept originally devised by academic researchers at the Karolinska Institute and seeing it through to being acquired by a world class company we have demonstrated the considerable value creation made possible by the Pharmalink model. We are very happy to see Grifols, our long standing partner, acquire and develop the PPS indication and to have played a part in bringing forward a treatment for this underserved condition."

Grifols will develop the PPS product opportunity using the acquired assets. Pharmalink will assist in technology trans
'/>"/>

SOURCE Pharmalink AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development
2. Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. BioVex Closes Second Round of Series E Financing
10. Pharmaxis Closes Share Purchase Plan
11. The closest look ever at native human tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Research ... the "Global N-acetylcysteine Industry Report 2014" ... Global N-acetylcysteine Industry Report 2014 is a professional ... the global N-acetylcysteine industry. The report ... definitions, classifications, applications and industry chain structure. The ...
(Date:9/18/2014)... 2014 Leatherwood Plastics has selected ... to stay competitive in the semiconductor, clean room ... ultimately impact product quality and productivity, according to ... Established in 1980 in Lewisville, TX, Leatherwood ... have left the business. Much of Leatherwood’s equipment ...
(Date:9/18/2014)... 18, 2014  Neogen Corporation (Nasdaq: NEOG ... strategic agreement with Merck Animal Health to market Neogen,s ... The Igenity Dairy Heifer Program consists of genomic tests ... genetic potential of replacement dairy heifers. The genomic tests ... and is an excellent tool in the decision-making process ...
(Date:9/18/2014)... , Sept. 18, 2014   Sigma-Aldrich ... it has entered into a new gene editing ... School,s Vector Core. Under the partnership, Sigma-Aldrich will ... experimental design consultation, and dedicated gene editing bioinformaticians. ... gene editing-based research at the U-M Medical School. ...
Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Merck Animal Health to market Neogen's dairy genomic program 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... - Laureate To Manufacture Alopexx,s Product Candidate -, ... Pharma, Inc.,a full-service biopharmaceutical development and protein production,company, ... cGMP contract,manufacturing agreement with Alopexx Pharmaceuticals, LLC. According ... antibody under cGMP,conditions. This antibody is planned for ...
... U.S. sales growth to $83.5 million, up 13 percent ... 42 percent over first-quarter 2007 -, CAMBRIDGE, Mass., ... today announced first-quarter 2008,U.S. net sales of $83.5 million ... the treatment of patients with relapsed multiple,myeloma. These results ...
... --- Carbon nanotubes are promising materials for many ... chemical, optical and electrical properties. , Now researchers ... make thin films that are semitransparent, highly conductive, ... with an appearance similar to stained glass. These ...
Cached Biology Technology:Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 2Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 3Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales 2Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales 3Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales 4Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales 5Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales 6Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales 7Carbon nanotubes made into conductive, flexible 'stained glass' 2
(Date:9/18/2014)... robotic system that can operate inside the bore of ... of a biomedical research partnership program at Brigham and ... if the robot, in conjunction with real-time MRI images, ... costly, and less discomforting for the patient. The novel ... therapies with greater precision. , Developed by a team ...
(Date:9/18/2014)... the International Space Station ever starts a "frequent flyers" ... status. Recently the orbiting laboratory has hosted increasing numbers ... returned from the space station in April, and another ... third experiment is planned to launch in December. , ... around the world-- and in space. Model organisms can ...
(Date:9/18/2014)... Americans to undertake jaunts into the countryside each year could ... a century, according to new research. , Climate change could ... States as summer temperatures linger later into the year, Princeton ... Biogeography . For instance, the paper birch a popular ... could change color one to three weeks later by ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4
... The International Association for the Study of Lung Cancer (IASLC) ... July 25 to 27 in Rio de Janeiro, Brazil. Nearly ... cancer research and treatment. Lung cancer kills more ... among the most challenging cancers to treat. Yet, there is ...
... at the University of Wisconsin-Milwaukee (UWM) have identified a catalyst ... cells (MFCs) as the currently used platinum catalyst, but at ... the investment in making microbial fuel cells is the cost ... energy conversion and storage devices. The material nitrogen-enriched ...
... GSA Bulletin postings include studies of the geomorphic ... British Columbia; seafloor images around Ross Island, obtained by ... into the fossil record of early Tertiary mammal evolution ... in Algeria; and a new contribution to the growing ...
Cached Biology News:Bringing down the cost of fuel cells 2GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more 2GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more 3GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more 4GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more 5GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more 6GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more 7